A B S T R A C T It has been demonstrated that gastrointestinal extracts contain substances which react immunologically with antibodies prepared to pancreatic glucagon. These extracts have been termed intestinal GLI for glucagon-like immunoreactivity, or enteroglucagon. To determine whether GLI has specific biological effects, studies were designed using the criterion of effect with antiglucagon antibodies. These antibodies did not cross-react with either secretin or pancreozymin.
Received for publication 12 Octobcr 1972 arcd in rczviscd form 4 Jan aryl 1973. that gastrointestinal extracts contained a substance which had certain biological properties in common with pancreatic glucagon. Unger, Eisentraut, Sims, McCall, and Madison (3) and Samols, Tyler, Megyesi, and Marks (4) subsequently reported that intestinal extracts cross-reacted with pancreatic glucagon antibodies. As a result, such extracts were termed intestinal GLI for glucagon-like immunoreactivity, or enteroglucagon. 1 Intestinal GLI of canine, bovine, and porcine origin have since been partially characterized on gel filtration (5) and ion exchange chromatography (6) .
In addition GLI has been shown to be present in serum and to be released into the circulation under a variety of circumstances (5, (7) (8) (9) .
The metabolic role of intestinal GLI is, however, not as yet understood. Unger, Ohneda, Valverde, Eisentraut, and Exton (7) reported that the injection of intestinal GLI in dogs caused an increase in immunoreactive insulin (IRI) release accompanied by a drop in blood sugar. These results suggested the hypothesis that. GLI may be the intestinal signal responsible for the greater IRI response to orally given glucose as compared to glucose given intravenously (10) . The same authors, however, later disclaimed this physiological role of GLI on IRI release since they observed that although several monosaccharides given intraduodenaly raised circulating GLI, this was not accompanied by a significant increase in plasma IRI levels (11) .
"In vitro" studies on the effects of GLI on IRI release rendered contradictory results. Buchanan, Vance, and Williams (12) failed to see any effect of intestinal GLI on IRI release from isolated islets. Fi(iURE 1 Gll and protein patterns of an acid-alcohol extract of rat small intestine. Two major Gl p eaks are noted. Peak I eltes as a larger molecnle, while peak 11 elntes in the area where p)ancreatic glucagon olutes.
Moody, Markussen, Schaich, Freis, Steenstruip, and Sundby (6) showed that several porcine intestinal fractions containing GLI produced IRI release. They indicated, however, that their data (lid not permit them to assess whether material possessing GLI is only associated with, or is, in fact, responsible for IRI release. Unknown, as well as known, intestinal hormones such as secretin and pancreozymin may contaminate intestinal (.LI extracts. Both secretin and pancreozymin appear to release IRI under certain circumstances (13) .
In order to determine whether GIA has specific biological effects on pancreas or adipose tissue, we designed studies using the criterion of suppressibility of GLI biological action bY antiglUcagon serum. This serum did not cross-react with either secretin or pancreozymin. These studies indicate that (GII ma be a causative agent in the release of IRI.
MIETHODS
Intestinal GLI extraction procedure Male, Sprague-D)awley rats (300-350 g) were used as intestine donors. Under Amytal anesthesis (66 mg,/kg) the smnall intestine was rap)idly dissected from a p)oint 3 cm below the angle of Treitz to the cecum. After being flushed with cold saline, the mucosa was scral)ed and immediately extracted in the cold, by the acid-alcohol procedure of Davoren (14) . IPooled miuicosa (wet weight 63--65 g) obtained fromt 12 fed rats was routinely' processed as a single batch with 1000 U I'r.lisvloljl1() g mucosa. As l)revioulsly reported by Heding (8) obtained from fed rats, cut into 100-120 mg pieces and, after a 20 min "wash-out" period in 60 mg/100 ml of glucose, transferred to the vessels containing the experimental medium. The actual experimental incubation consisted of three sequential incubation periods of 30 min each at 370C in a Dubnoff shaker. No glucose was added to the medium in the first incubation period. In the second and third period glucose was added to a concentration of 100 and 300 mg/100 ml, respectively. At the end of each period, the medium was sampled for IRI. Each point of observation consisted of three to six vessels. Glucose controls were run with each experiment. An experiment was carried out to determine whether glucagon remains intact under the conditions described above.
[1251 ]_ glucagon (50 ng/ml) was incubated as above for 60 min. The Sephadex filtration pattern before and after incubation remained essentially unchanged. Studies on rat epididymal fat pad. All experiments were paired and run in duplicate, with one fat pad (cut in three pieces and placed in three vessels) as a control and the other fat pad (three vessels) as the experimental series. As described in the studies with pancreas pieces, GLI was preincubated for 30 min at 370C in the incubation medium before the tissue was added to the vessel.
(a). Studies on FFA release were carried out as previously described (16 PEAK GLI ng/ml FIGURE 3 The in vitro effect of peak I GLI on insulin release from rat pancreas pieces is shown as the increment over controls.
washed with ether and finally lyophilized. cAMP determinations were carried out by the method of Gilman (17) . Antibody suppression studies. The effect of the addition of L-67 AG-GPS was studied upon the release of IRI or fat pad cAMP in the presence and absence of GLI, secretin, or pancreatic glucagon. Three types of vessels were prepared and preincubated for 30 min at 370C before adding the tissues to the vessels: (a) the hormone or extract alone, (b) the hormone or extract plus L-67 AG-GPS, and (c) the hormone or extract plus normal (nonimmunized) guinea pig serum (N-GPS). The final antiserum concentration used was 1:250 since approximately 75% of 50 ng/ml of GLI were bound to the antibody under the experimental conditions above mentioned.
Liver perfusions. Closed circuit liver perfusions were carried out using overnight fasted rat livers as previously described (18) . The perfusate was Krebs-Henseleit bicarbonate buffer pH 7.4 with 1% human albumin and 3%" Dextran (T-40). After a 30 min equilibrium period, eluates containing peak I or peak II of intestinal GLI or pancreatic glucagon were added to the perfusate. 5 (Table I and Fig. 1 ).
Extracts of mucosa from duodenum and stomach showed on gel filtration different concentrations of both GLI peaks. On mucosal wet weight basis peak I GLI was diminished in the duodenum and strikingly diminished in the stomach as compared to the small intestine. The concentrations of peak II GLI also decreased, but these changes were much less pronounced. As a result, the ratio peak I GLI/peak II GLI fell from 1.52 in the small intestine to 0.66 in the duodenum and 0.41 in the stomach (Table II) .
The nutritional status of the animal affected the small intestine concentrations of both GLI peaks. Table III shows that although both peaks were diminished, starvation preferentially affected peak I GLI. Consequently, the ratio peak I GLI/peak II GLI fell to 1.33 and 0.91 at 24 and 48 h of fasting, respectively. Table I lists the concentration of measured components in each GLI peak. Secretin and pancreozymin as estimated by bioassay were undetectable in the peak I GLI pool and were present in very small amounts in the pool of peak II GLI.
GLI effect on IRI release from pancreas pieces. Both GLI peaks stimulated IRI release from pancreas pieces in the absence of glucose. In addition, they also potentiated the effect of either 100 or 300 mg/100 ml of glucose (Figs. 3 and 4 , Table IV ). Peak I GLI produced an increasing IRI-releasing effect when concentrations between 10 and 400 ng/ml GLI were used at any of the three glucose concentrations tested. Peak II GLI showed what seemed to be a dose-dependent IRI release between 0.3 and 4 ng/ml. The IRI responses were plateaued when doses between 4 and 10 ng GLI/ml were tested. This IRI-releasing pattern was similar at any glucose concentration. From 30 to 100 ng GLI/ml, an inhibitory effect was seen on the IRI release, particularly that induced by 300 mg/100 ml of glucose. 50 ng/ml of pancreatic glucagon had no effect on IRI release at any glucose concentration tested (Table V) .
Up to 3 U/ml of pure pancreozymin did not stimulate IRI release at 0 or 100 mg/100 of glucose. Wrhen (Table V) . The presence of L-67 antiglucagon serum (AG-GPS) in the incubation medium had no effect on the capacity of peak I GLI to release IRI (Table VI) . In contrast, it significantly inhibited the IRI release produced by peak II GLI. 53%, 67%, and 51% inhibition of the peak II GLI effect was seen at 0, 100, and 300 mg/100 ml of glucose, respectively. 5 and Tables VII and VIII). Both GLI peaks increased tissue cAMP levels and FFA release from epididymal fat pad (Table VII) . Increasing concentrations of peak II GLI between 32 and 672 ng/ml resulted in a progressive and parallel increase in both tissue cAMP levels and FFA release into the incubation medium (Fig. 5) . In contrast, 900 ng/ml of peak I GLI were required to obtain a minimal response (Table VII) . 100 Effects of perfusion of intestinal GLI and pancreatic glucagon through isolated rat liver (Fig. 6 ). Glucagon immunoreactivity of native pancreatic glucagon disappeared from the liver perfusate with a to of approximately 4 min. In contrast, immunoreactivity from either peak I or peak II GLI was essentially unaffected * P values designated in the footnote of Table IV. t The GLI effect was calculated as the increment in IRI over the respective glucose control. The percent inhibition of the GlI effect by AG-GPS was then calculated as follows:
100 X (GLI effect) -(GLI effect in AG-GPS) ( IRI-releasing effects of each peak were compared, four major differences emerged. First, peak I GLI produced optimal IRI release at 100 mg/100 ml of glucose while 300 mg/100 ml seemed to be optimal for peak II. This was clearly evidenced when the increments in IRI over the glucose controls were plotted ( Fig. 4 and 5) . A second difference was found in the characteristics of the respective dose-response curves. Peak I GLI produced a progressive increase in IRI release with increasing GLI concentrations. In contrast, the results obtained with peak II GLI suggested that at concentrations between and above 4-10 ng/ml, an inhibitor was present in the extract. Two known inhibitors of IRI release, serotonin (21) and epinephrine (22) , are present in gastrointestinal mucosa and could have been contaminating our extracts. Whatever the nature of this inhibitor, it could explain why the GLI of some intestinal extracts was reported to have no IRI-releasing activity (23) . It could also account for the fact that no quantitative correlation was found II GLI. A lipolytic effect of dog jejunal GLI peaks has previously been shown (26) . L-67 AG-GPS suppressed 60-70% of the cAMP elevation induced by peak II GLI, indicating that most of the effects on adipose tissue associated with peak II are specifically induced by the GLI present in that fraction. The nonsuppressible activity could be accounted for either by GLI not bound by antibody or by the secretin present in peak II GLI. The latter seems likely since it has been shown (27) that even very low concentrations of secretin (0.1 U/ml) are lipolytic in fat pad. Pancreozymin has been shown to have no effect on FFA release from fat pad (16) .
When GLI effects on fat pad were compared to the GLI effects on IRI release, three major differences were evident. In the first place, the threshold for the fat pad response was approximately 10 and 30 times higher for peak I and II, respectively, when compared to the threshold for IRI release. Secondly, no inhibitory phase was evident in fat pad when large doses of peak II GLI were used. Thus, whatever the nature of the inhibitor, it appears to have affected only the IRI response to GLI. Finally, when roughly immunoequivalent amounts of peak II GLI and pancreatic glucagon were compared, they proved to be similarly effective in stimulating cAMP levels and FFA release from adipose tissue. In contrast, as regards IRI release, the biological activity per unit of immunological reactivity was strikingly higher for either GLI peak when compared to pancreatic glucagon. One additional difference between intestinal GLI and pancreatic glucagon was of particular interest. While the liver destroyed the immunoreactivity of pancreatic glucagon with a ti of approximately 4 min, it had almost no effect on either GLI peak. Assan (a) The mol wt of peak II GLI and pancreatic glucagon are similar suggesting that the number of amino acids in both molecules are similar also, possibly 29. (b) The 24-29 sequence present in peak II GLI must be sequentially different from pancreatic glucagon since the antiglucagon serum specific for pancreatic glucagon reacts very poorly with peak II GLI. Further support for this contention may be found in the fact that immunoequivalent amounts of peak II had much greater IRI-releasing activity than pancreatic glucagon.
(c) Sequence 19-23 is probably similar in peak II GLI and glucagon since effects on fat pad were comparable when immunoequivalent doses of both were used.
Our data does not permit us to make any speculations concerning the structure or the biological effects of peak I GLI. On the other hand, a significant physiologic role for peak II GLI as an intestinal signal for IRI release after glucose can be postulated for the following reasons:
(a) Fasting results in marked decreases of intestinal content of GLI suggesting that the ingestion of nutrients may regulate GLI.
(b) Both GLI peaks are secreted into the mesenteric vein after the administration of glucose (29) . Since the liver did not affect the immunoreactive properties of either GLI peak, it could be assumed that in contrast with pancreatic glucagon, the liver does not degrade GLI. If this assumption is correct, both peaks would be available to peripheral target tissues.
(c) And finally, the greater potency of GLI on IRI release compared with the effects on adipose tissue focus upon the pancreas as the major target organ for GLI. ACKNOWLEDGMENT This work was supported by Veterans Administration and NIH Grant AM 11578.
